ECYT - Endocyte, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
18.21
+0.68 (+3.88%)
As of 3:08PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close17.53
Open17.46
Bid18.19 x 1000
Ask18.20 x 800
Day's Range17.38 - 18.32
52 Week Range1.36 - 20.85
Volume605,190
Avg. Volume1,328,979
Market Cap1.479B
Beta0.11
PE Ratio (TTM)N/A
EPS (TTM)-0.96
Earnings DateMay 7, 2018 - May 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est23.33
Trade prices are not sourced from all markets
  • GlobeNewswire10 days ago

    Endocyte Announces Closing of Public Offering of Common Stock

    Endocyte, Inc. (Nasdaq Global Market:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, announced today the closing of an underwritten registered public offering of an aggregate of 10,878,379 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase additional shares of common stock, at a price to the public of $18.50 per share. All shares of common stock sold in the offering were sold by Endocyte. Endocyte received aggregate net proceeds from the offering of approximately $188.7 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by Endocyte.

  • Pharma/Biotech Stocks to Watch This Prostate Cancer Month
    Zacks10 days ago

    Pharma/Biotech Stocks to Watch This Prostate Cancer Month

    Here we highlight a few companies that are focused on developing treatments for prostate cancer.

  • Benzinga12 days ago

    The Daily Biotech Pulse: Foamix Jumps on Data, Positive Results for Galapagos-Gilead's Rheumatoid Arthritis Drug, Bausch Health Trims Debt

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 11.) BioSpecifics Technologies Corp. (NASDAQ: BSTC ) Genomic ...

  • Analysts Are Bullish on Verastem in September
    Market Realist12 days ago

    Analysts Are Bullish on Verastem in September

    On September 11, Verastem (VSTM) stock closed at $9.17, which is ~13% below its 52-week high of $10.35 on September 4. On September 6, Verastem announced that the company completed dosing the first patient with duvelisib and venetoclax combination therapy for the multicenter phase 1/2 trial at the Dana-Farber Cancer Center. Verastem is evaluating the safety and efficacy of duvelisib and venetoclax combination therapy for the treatment of individuals with relapsed or refractory chronic lymphoblastic leukemia or small lymphocytic lymphoma.

  • GlobeNewswire13 days ago

    Endocyte Announces Pricing of Public Offering of Common Stock

    Endocyte, Inc. (Nasdaq Global Market:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, announced today the pricing of an underwritten registered public offering of 9,459,460 shares of its common stock at a price to the public of $18.50 per share.  In addition, Endocyte granted the underwriters a 30-day option to purchase up to an additional 1,418,919 shares of its common stock on the same terms and conditions. All shares of common stock sold in the offering are being sold by Endocyte. Endocyte expects to close the offering on or about September 14, 2018, subject to the satisfaction of customary closing conditions.

  • Why Endocyte’s Stock Price Rose 11.4% Yesterday
    Market Realist13 days ago

    Why Endocyte’s Stock Price Rose 11.4% Yesterday

    Today, Endocyte stock is trading at $19.16, which reflects ~1.43% growth from yesterday’s closing price of $18.89. Yesterday, the stock price grew ~11.38% to reach $18.89, versus its close of $16.96 the day before. Endocyte hit a 52-week high of $20.85 on September 4. It hit a 52-week low of $1.36 on September 28, 2017. Reason for growth

  • Endocyte Announces FDA's Acceptance of Trial Endpoint Change
    Zacks13 days ago

    Endocyte Announces FDA's Acceptance of Trial Endpoint Change

    177Lu-PSMA-617, a prostate specific membrane antigen-targeted radioligand therapy, is Endocyte's (ECYT) lead program. It is being evaluated in a phase III study for mCRPC for PSMA-positive patients

  • Company News For Sep 11, 2018
    Zacks13 days ago

    Company News For Sep 11, 2018

    Companies in the news are: NKE, SAIC, EGL, BABA and ECYT

  • Endocyte (ECYT) Soars: Stock Adds 11.4% in Session
    Zacks13 days ago

    Endocyte (ECYT) Soars: Stock Adds 11.4% in Session

    Endocyte (ECYT) saw a big move last session, as its shares jumped more than 11% on the day, amid huge volumes.

  • Benzinga13 days ago

    The Daily Biotech Pulse: Advaxis Posts Narrower Loss, Endocyte Announces $175M Offering, Leadership Transition At Insulet

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Stocks that hit 52-week highs Sept. 7.) Amgen, Inc. (NASDAQ: AMGN )/p BioSpecifics Technologies ...

  • ACCESSWIRE13 days ago

    Today's Research Reports on Trending Tickers: Amgen and Endocyte

    The Dow Jones Industrial Average declined 0.23 percent to close at 25,857.07, while the S&P 500 Index increased 0.19 percent to close at 2,877.13. The Nasdaq Composite Index gained 0.27 percent to close at 7,924.16. Amgen's stock jumped 3.16% Monday, to close the day at $202.50.

  • 3 Surging Biotech Stocks -- Can They Keep Climbing?
    Motley Fool13 days ago

    3 Surging Biotech Stocks -- Can They Keep Climbing?

    Here's what needs to happen to see more gains from these high-flying drugmakers.

  • CNBC14 days ago

    After-hours buzz: SONO, NTNX & more

    Sonos SONO stock plunged more than 13 percent in after-hours trading after reporting third-quarter earnings , the company's first quarterly earnings report since its initial public offering in August. Casey's General Stores CASY stock rose over 3 percent in after-hours trading after the company reported first-quarter earnings that beat analysts' expectations. The convenience store chain reported $2.59 billion in revenue, higher than the $2.58 billion analysts expected.

  • Here's Why Endocyte Jumped Higher Today and Is Down After Hours
    Motley Fool14 days ago

    Here's Why Endocyte Jumped Higher Today and Is Down After Hours

    A quicker pathway to approval had shares up, then the company decided to use the opportunity to raise additional capital.

  • GlobeNewswire14 days ago

    Endocyte Announces $175.0 Million Proposed Public Offering of Common Stock

    Endocyte, Inc. (Nasdaq Global Market:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, announced today that it intends to offer and sell $175.0 million of its common stock in an underwritten registered public offering.  In addition, Endocyte expects to grant the underwriters a 30-day option to purchase up to an additional $26.25 million of its common stock on the same terms and conditions. All shares of common stock to be sold in the proposed offering will be sold by Endocyte. Endocyte intends to use the net proceeds from the proposed offering, if completed, to fund the continued clinical development of its pipeline products and preparation for the commercial launch of 177Lu-PSMA-617, if approved, as well as for working capital and general corporate purposes.

  • GlobeNewswire14 days ago

    Endocyte Announces FDA Acceptance of Radiographic Progression Free Survival (rPFS) as an Alternative Primary Endpoint of the VISION Trial in Addition to Overall Survival (OS)

    Endocyte, Inc. (ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that following a meeting with the U.S. Food and Drug Administration (FDA), it was determined that rPFS is an appropriate efficacy endpoint in the ongoing phase 3 VISION trial to support the submission of a New Drug Application (NDA) for full FDA approval of 177Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer (mCRPC). “We are very pleased with the FDA’s support of the rPFS endpoint as the basis for a submission for full approval of 177Lu-PSMA-617.

  • Is the Options Market Predicting a Spike in Endocyte (ECYT) Stock?
    Zacks17 days ago

    Is the Options Market Predicting a Spike in Endocyte (ECYT) Stock?

    Investors need to pay close attention to Endocyte (ECYT) stock based on the movements in the options market lately.

  • Endocyte (ECYT) Up 14.6% Since Last Earnings Report: Can It Continue?
    Zacks25 days ago

    Endocyte (ECYT) Up 14.6% Since Last Earnings Report: Can It Continue?

    Endocyte (ECYT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • GlobeNewswire26 days ago

    Endocyte to Present at Wells Fargo Securities 2018 Healthcare Conference

    Endocyte, Inc. (ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that the company’s management team will present at the Wells Fargo Securities 2018 Healthcare Conference on Wednesday, Sept. 5, at 3:00 p.m. EDT. A live audio webcast of the Company’s presentation can be accessed by visiting “Events & Presentations” under the Investors & News section of Endocyte’s website at www.endocyte.com. The webcast will be archived shortly after the live event, and a replay will be available on the Company’s website for 90 days following the conference.

  • GlobeNewswire27 days ago

    UPDATE - Endocyte Announces Presentations at the CAR-TCR Summit 2018

    WEST LAFAYETTE, Ind., Aug. 28, 2018-- Endocyte, Inc., a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that data from the Company’ s chimeric ...

  • GlobeNewswire27 days ago

    Endocyte Announces Presentations at the CAR-TCR Summit 2018

    WEST LAFAYETTE, Ind., Aug. 28, 2018-- Endocyte, Inc., a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that data from the Company’ s chimeric ...

  • GlobeNewswirelast month

    Endocyte Announces Presentations at the American Chemical Society (ACS) National Meeting & Exposition

    WEST LAFAYETTE, Ind., Aug. 17, 2018-- Endocyte, Inc., a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that two posters will be presented ...

  • GlobeNewswire2 months ago

    Endocyte to Present at the 2018 Wedbush PacGrow Healthcare Conference

    Endocyte, Inc. (ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that the company’s management team will present at the 2018 Wedbush PacGrow Healthcare Conference on Tuesday, Aug. 14, at 3:40 p.m. EDT. A live audio webcast of the Company’s presentation can be accessed by visiting “Events & Presentations” under the Investors & News section of Endocyte’s website at www.endocyte.com. The webcast will be archived shortly after the live event, and a replay will be available on the Company’s website for 90 days following the conference.

  • GlobeNewswire2 months ago

    Recent Analysis Shows Eaton Vance, Endocyte, Ion Geophysical, Macerich, SunCoke Energy, and Dolby Laboratories Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, Aug. 03, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Eaton ...

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of ECYT earnings conference call or presentation 31-Jul-18 12:30pm GMT

    Q2 2018 Endocyte Inc Earnings Call